Announcements Trials
Browse Landscape

Phase

Phase NA 5

Status

Recruiting 3Not yet recruiting 1Completed 1

Sponsor Class

OTHER 5

Study Type

Interventional 5Observational 2

Sponsor

Cancer Type

Genitourinary 5Gynecologic 2Breast 2Sarcoma 1Gastrointestinal 1Dermatologic 1

Conditions

Prostatic Neoplasms 5Breast Neoplasms 5Ovarian Neoplasms 4Pancreatic Neoplasms 3Colorectal Neoplasms, Hereditary Nonpolyposis 3Triple Negative Breast Neoplasms 2Neoplastic Syndromes, Hereditary 2Hereditary Breast and Ovarian Cancer Syndrome 2Endometrial Neoplasms 2Colorectal Neoplasms 2Urogenital Neoplasms 1Sarcoma 1Rectal Neoplasms 1Neoplasms, Unknown Primary 1Multiple Myeloma 1Melanoma 1Lymphoproliferative Disorders 1Kidney Neoplasms 1Hematologic Neoplasms 1Head and Neck Neoplasms 1Fanconi Anemia, Complementation Group D1 1Digestive System Neoplasms 1Cytopenia 1Congenital Bone Marrow Failure Syndromes 1Colonic Neoplasms 1Central Nervous System Neoplasms 1Carcinoma, Ovarian Epithelial 1Carcinoma, Intraductal, Noninfiltrating 1Cancer Risk Syndrome 1Breast Neoplasms, Male 1

Interventions

Docetaxel 277Prednisone 236enzalutamide 175Leuprolide 172Radiotherapy 164Abiraterone Acetate 153Magnetic Resonance Spectroscopy 147bicalutamide 137Goserelin 134Androgen Antagonists 111Radiosurgery 101acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 100apalutamide 78abiraterone 75gallium 68 PSMA-11 74Specimen Handling 67Gonadotropin-Releasing Hormone 58darolutamide 56Radiation 56Triptorelin Pamoate 53cabazitaxel 49Zoledronic Acid 49pembrolizumab 48Radiotherapy, Intensity-Modulated 47Flutamide 47Brachytherapy 47luprolide acetate gel depot 46Standard of Care 45Carboplatin 44Estramustine 43

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Interventional × Prostatic Neoplasms × Genetic Counseling × Clear all
NCT05225428 2026-05-22

VERDI

Dana-Farber Cancer Institute

Phase NA Recruiting
1,020 enrolled
BreastDermatologicGastrointestinalGenitourinaryGynecologicSarcoma

Breast Neoplasms, Kidney Neoplasms, Melanoma, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Sarcoma, Colorectal Neoplasms

NCT05487846 2026-04-14

Peer Navigation for the Support of Metastatic Prostate Cancer Patients Undergoing Genetic Evaluation

Thomas Jefferson University

Phase NA Recruiting
120 enrolled
Genitourinary

Prostatic Neoplasms

NCT06422455 2026-03-18

Access to Genetic Testing in Underserved Patients With Cancer

University of Southern California

Phase NA Recruiting
800 enrolled
BreastGenitourinaryGynecologic

Breast Neoplasms, Ovarian Neoplasms, Prostatic Neoplasms, Breast Neoplasms, Male, Triple Negative Breast Neoplasms

NCT07377006 2026-02-18

Decision Support Tool to Enhance Germline Genetic Testing for Patients With Prostate Cancer

M.D. Anderson Cancer Center

Phase NA Not yet recruiting
108 enrolled
Genitourinary

Prostatic Neoplasms

NCT04447703 2025-12-02

Technology-Enhanced Acceleration of Germline Evaluation for Therapy, TARGET Study

Thomas Jefferson University

Phase NA Completed
346 enrolled
Genitourinary

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡